Wednesday, December 9, 2009

International Stem Cell Corporation Announces Launch Strategy for Skin Care Product Line

Lifeline Skin Care, Inc, a wholly owned subsidiary of International Stem Cell Corporation (OTCBB:ISCO),, announced today that it has retained the services of a highly experienced expert in the skin care industry, Raulee Marcus, to help design a marketing program for its newly created line of skin care products based on ISCO's proprietary Parthenogenic Stem Cells.

Ms. Marcus has an extensive background in skin care products, having been a key corporate executive with responsibilities for marketing, R&D and sales at companies such as Neutrogena, Colgate-Palmolive and Gillette, increasing sales at those companies by many millions of dollars. She has also had a highly successful career in building revenues and profits for smaller companies such as Obagi Medical Products, a physician-mediated company, and has extensive experience in launching new brands and products through many different channels.

"Ms. Marcus is uniquely qualified to help us develop a product strategy that will have maximum market impact for what is truly a unique technology," said Dr. Ruslan Semechkine, President of Lifeline Skin Care.

"Ms. Marcus' experience in the skin care industry and as a consultant to companies in that industry will greatly enhance our ability to develop a successful marketing and business strategy without distracting from our core focus on developing therapeutic products from Parthenogenic Stem Cells," said Kenneth Aldrich, Chairman of ISCO.

"Early indications are that the skin care product, developed through the efforts of the ISCO scientists who created Parthenogenic Stem Cells, has unique characteristics for skin rejuvenation. Our next step is to validate these findings through independent testing and execute our product launch," said Dr. Semechkine.


International Stem Cell Corporation is a California biotechnology company focused on developing therapeutic and research products. ISCO's technology, Parthenogenesis, results in the creation of pluripotent human stem cell lines from unfertilized human eggs. ISCO scientists have created the first Parthenogenetic homozygous stem cell line (phSC-Hhom-4) that can be a source of therapeutic cells that will minimize immune rejection after transplantation into hundreds of millions of individuals of differing sexes, ages and racial groups. These advancements offer the potential to create the first true "Stem Cell Bank" and address ethical issues by eliminating the need to use or destroy fertilized embryos. ISCO also produces and markets specialized cells and growth media worldwide for therapeutic research through its subsidiary Lifeline Cell Technology. For more information, visit the ISCO website at:

To subscribe to receive ongoing corporate communications please click on the following link:


Statements pertaining to anticipated future financial and/or operating results, future growth in research, technology, clinical development and potential joint venture and other opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Brian Lundstrom, President
The Investor Relations Group
Media Relations:
Laura Colontrelle
Investor Relations:
James Carbonara

No comments:

Post a Comment